• Policy
• The HIRA also decided to disclose the results of Kymriah
• by Lee, Hye-Kyung Oct 15, 2021 05:58am

• Policy
• Requests for confirmation of medical expenses, disclosed
• by Lee, Hye-Kyung Oct 15, 2021 05:57am

• Company
• Rediscovery of Clopidogrel brings back generic boom
• by Kim, Jin-Gu Oct 15, 2021 05:57am

• Policy
• A new drug preferential law will be promoted
• by Lee, Jeong-Hwan Oct 15, 2021 05:57am

• Company
• ‘Ibrance’ opens new horizon as the lead CDK4/6 inhibitor
• by Oct 14, 2021 05:38am

• Policy
• No need to extend the benefit period of Keytruda
• by Lee, Jeong-Hwan Oct 14, 2021 05:38am

• Policy
• Poor ‘Benefit Adequacy Assessment' in controversy
• by Lee, Jeong-Hwan Oct 14, 2021 05:38am

• Company
• Korea Otsuka Pharma’s Hyangnam Plant rises as a global hub
• by Nho, Byung Chul Oct 14, 2021 05:38am

• Policy
• # of COVID-19 confirmed medical staff doubled in 3 months
• by Lee, Jeong-Hwan Oct 14, 2021 05:37am

• Policy
• Suspicions of preferential tx for SK Bioscience & Celltrion
• by Lee, Tak-Sun Oct 14, 2021 05:37am